[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fgAl7Z1XFHJnsIz4XSEc3i5I1vqCnKInQ052Afd94NVQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":40,"rows":47},"Janssen-Cilag International NV",[4],67,false,1,24,26232,4,[13,16,19,22,25,27,30,32],{"name":14,"count":15},"Healthy",19,{"name":17,"count":18},"Schizophrenia",11,{"name":20,"count":21},"Multiple Myeloma",6,{"name":23,"count":24},"Psoriasis",3,{"name":26,"count":24},"Hepatitis C, Chronic",{"name":28,"count":29},"Hepatitis C",2,{"name":31,"count":29},"Pain",{"name":33,"count":8},"Kidney Failure, Chronic",[35],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT03218488","A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis","2032-08-31","Ustekinumab",[41,42,43,44,45,46],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[48,82,109,127,145,177,195,213,231,249,267,285,303,321,391,449,486,512,534,556,598,647,669,691,734,770,803,827,853,871,897,915,942,960,978,1003,1028,1046,1064,1082,1100,1118,1136,1154,1172,1190,1208,1226,1244,1262,1280,1298,1316,1334,1361,1379,1397,1422,1440,1465,1483,1516,1534,1552,1570,1588,1606,1624,1642,1687,1730,1765,1800,1824,1842,1860,1878,1901,1919,1942,1964,1982,2009,2027,2045,2063,2081,2106,2124,2142,2168,2186,2204,2222,2240,2258,2283,2301,2328,2346,2364,2382,2400,2424,2449,2467,2498,2516,2534,2552,2570,2588,2606,2624,2642,2666,2684,2702,2725,2743,2766,2790,2814],{"intervention":39,"totalTrials":29,"cells":49},{"EARLY_PHASE1":50,"PHASE1":53,"PHASE2":55,"PHASE3":57,"PHASE4":59,"NA":73},{"trials":51,"activeCount":52},[],0,{"trials":54,"activeCount":52},[],{"trials":56,"activeCount":52},[],{"trials":58,"activeCount":52},[],{"trials":60,"activeCount":52},[61],{"nctId":62,"briefTitle":63,"status":64,"phases":65,"primaryCompletion":66,"completion":67,"start":68,"enrollment":69,"conditions":70,"interventions":71},"NCT01059773","A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate","COMPLETED",[45],"2010-11","2011-08","2009-10",490,[23],[39,72],"Methotrexate",{"trials":74,"activeCount":8,"soonestReadout":38},[75],{"nctId":36,"briefTitle":37,"status":76,"phases":77,"primaryCompletion":38,"completion":38,"start":78,"enrollment":79,"conditions":80,"interventions":81},"ACTIVE_NOT_RECRUITING",[],"2017-10-25",135,[23],[39],{"intervention":83,"totalTrials":8,"cells":84},"IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem",{"EARLY_PHASE1":85,"PHASE1":87,"PHASE2":89,"PHASE3":91,"PHASE4":93,"NA":107},{"trials":86,"activeCount":52},[],{"trials":88,"activeCount":52},[],{"trials":90,"activeCount":52},[],{"trials":92,"activeCount":52},[],{"trials":94,"activeCount":52},[95],{"nctId":96,"briefTitle":97,"status":64,"phases":98,"primaryCompletion":99,"completion":99,"start":100,"enrollment":101,"conditions":102,"interventions":105},"NCT00996177","A Study to Compare Patient-controlled Pain Medications Delivered Either Through the Skin or Intravenously",[45],"2005-04","2004-06",657,[31,103,104],"Analgesia, Patient-Controlled","Pain, Postoperative",[83,106],"IV Morphine Patient-Controlled Analgesia",{"trials":108,"activeCount":52},[],{"intervention":106,"totalTrials":8,"cells":110},{"EARLY_PHASE1":111,"PHASE1":113,"PHASE2":115,"PHASE3":117,"PHASE4":119,"NA":125},{"trials":112,"activeCount":52},[],{"trials":114,"activeCount":52},[],{"trials":116,"activeCount":52},[],{"trials":118,"activeCount":52},[],{"trials":120,"activeCount":52},[121],{"nctId":96,"briefTitle":97,"status":64,"phases":122,"primaryCompletion":99,"completion":99,"start":100,"enrollment":101,"conditions":123,"interventions":124},[45],[31,103,104],[83,106],{"trials":126,"activeCount":52},[],{"intervention":72,"totalTrials":8,"cells":128},{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":137,"NA":143},{"trials":130,"activeCount":52},[],{"trials":132,"activeCount":52},[],{"trials":134,"activeCount":52},[],{"trials":136,"activeCount":52},[],{"trials":138,"activeCount":52},[139],{"nctId":62,"briefTitle":63,"status":64,"phases":140,"primaryCompletion":66,"completion":67,"start":68,"enrollment":69,"conditions":141,"interventions":142},[45],[23],[39,72],{"trials":144,"activeCount":52},[],{"intervention":146,"totalTrials":8,"cells":147},"Risperidone 3 mg",{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":175},{"trials":149,"activeCount":52},[],{"trials":151,"activeCount":52},[],{"trials":153,"activeCount":52},[],{"trials":155,"activeCount":52},[],{"trials":157,"activeCount":52},[158],{"nctId":159,"briefTitle":160,"status":64,"phases":161,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":166},"NCT04940039","A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings",[45],"2024-04-16","2021-07-22",93,[17],[146,167,168,169,170,171,172,173,174],"Paliperidone Palmitate 50 mg eq.","Paliperidone Palmitate 75 mg eq.","Paliperidone Palmitate 100 mg eq.","Paliperidone Palmitate 150 mg eq.","Paliperidone Palmitate 175 mg eq.","Paliperidone Palmitate 263 mg eq.","Paliperidone Palmitate 350 mg eq.","Paliperidone Palmitate 525 mg eq.",{"trials":176,"activeCount":52},[],{"intervention":167,"totalTrials":8,"cells":178},{"EARLY_PHASE1":179,"PHASE1":181,"PHASE2":183,"PHASE3":185,"PHASE4":187,"NA":193},{"trials":180,"activeCount":52},[],{"trials":182,"activeCount":52},[],{"trials":184,"activeCount":52},[],{"trials":186,"activeCount":52},[],{"trials":188,"activeCount":52},[189],{"nctId":159,"briefTitle":160,"status":64,"phases":190,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":191,"interventions":192},[45],[17],[146,167,168,169,170,171,172,173,174],{"trials":194,"activeCount":52},[],{"intervention":168,"totalTrials":8,"cells":196},{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":203,"PHASE4":205,"NA":211},{"trials":198,"activeCount":52},[],{"trials":200,"activeCount":52},[],{"trials":202,"activeCount":52},[],{"trials":204,"activeCount":52},[],{"trials":206,"activeCount":52},[207],{"nctId":159,"briefTitle":160,"status":64,"phases":208,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":209,"interventions":210},[45],[17],[146,167,168,169,170,171,172,173,174],{"trials":212,"activeCount":52},[],{"intervention":169,"totalTrials":8,"cells":214},{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":221,"PHASE4":223,"NA":229},{"trials":216,"activeCount":52},[],{"trials":218,"activeCount":52},[],{"trials":220,"activeCount":52},[],{"trials":222,"activeCount":52},[],{"trials":224,"activeCount":52},[225],{"nctId":159,"briefTitle":160,"status":64,"phases":226,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":227,"interventions":228},[45],[17],[146,167,168,169,170,171,172,173,174],{"trials":230,"activeCount":52},[],{"intervention":170,"totalTrials":8,"cells":232},{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":247},{"trials":234,"activeCount":52},[],{"trials":236,"activeCount":52},[],{"trials":238,"activeCount":52},[],{"trials":240,"activeCount":52},[],{"trials":242,"activeCount":52},[243],{"nctId":159,"briefTitle":160,"status":64,"phases":244,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":245,"interventions":246},[45],[17],[146,167,168,169,170,171,172,173,174],{"trials":248,"activeCount":52},[],{"intervention":171,"totalTrials":8,"cells":250},{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":255,"PHASE3":257,"PHASE4":259,"NA":265},{"trials":252,"activeCount":52},[],{"trials":254,"activeCount":52},[],{"trials":256,"activeCount":52},[],{"trials":258,"activeCount":52},[],{"trials":260,"activeCount":52},[261],{"nctId":159,"briefTitle":160,"status":64,"phases":262,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":263,"interventions":264},[45],[17],[146,167,168,169,170,171,172,173,174],{"trials":266,"activeCount":52},[],{"intervention":172,"totalTrials":8,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":275,"PHASE4":277,"NA":283},{"trials":270,"activeCount":52},[],{"trials":272,"activeCount":52},[],{"trials":274,"activeCount":52},[],{"trials":276,"activeCount":52},[],{"trials":278,"activeCount":52},[279],{"nctId":159,"briefTitle":160,"status":64,"phases":280,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":281,"interventions":282},[45],[17],[146,167,168,169,170,171,172,173,174],{"trials":284,"activeCount":52},[],{"intervention":173,"totalTrials":8,"cells":286},{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":293,"PHASE4":295,"NA":301},{"trials":288,"activeCount":52},[],{"trials":290,"activeCount":52},[],{"trials":292,"activeCount":52},[],{"trials":294,"activeCount":52},[],{"trials":296,"activeCount":52},[297],{"nctId":159,"briefTitle":160,"status":64,"phases":298,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":299,"interventions":300},[45],[17],[146,167,168,169,170,171,172,173,174],{"trials":302,"activeCount":52},[],{"intervention":174,"totalTrials":8,"cells":304},{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":311,"PHASE4":313,"NA":319},{"trials":306,"activeCount":52},[],{"trials":308,"activeCount":52},[],{"trials":310,"activeCount":52},[],{"trials":312,"activeCount":52},[],{"trials":314,"activeCount":52},[315],{"nctId":159,"briefTitle":160,"status":64,"phases":316,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":317,"interventions":318},[45],[17],[146,167,168,169,170,171,172,173,174],{"trials":320,"activeCount":52},[],{"intervention":322,"totalTrials":323,"cells":324},"bortezomib",5,{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":376,"PHASE4":387,"NA":389},{"trials":326,"activeCount":52},[],{"trials":328,"activeCount":52},[],{"trials":330,"activeCount":52},[331,344,355,365],{"nctId":332,"briefTitle":333,"status":334,"phases":335,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":340},"NCT00441168","Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma","TERMINATED",[43],"2008-01","2006-12",30,[20],[341,322,342,343],"adriamycin","dexamethasone","vincristine",{"nctId":345,"briefTitle":346,"status":64,"phases":347,"primaryCompletion":348,"completion":349,"start":350,"enrollment":351,"conditions":352,"interventions":353},"NCT00431769","An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma",[43],"2009-02","2010-01","2006-06",130,[20],[354],"Bortezomib",{"nctId":356,"briefTitle":357,"status":64,"phases":358,"primaryCompletion":359,"completion":360,"start":361,"enrollment":362,"conditions":363,"interventions":364},"NCT01286077","Velcade Consolidation Bone Study",[43],"2012-11","2014-04","2009-09",106,[20],[322],{"nctId":366,"briefTitle":367,"status":64,"phases":368,"primaryCompletion":67,"completion":67,"start":369,"enrollment":370,"conditions":371,"interventions":372},"NCT00908232","Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD",[43],"2008-05",163,[20],[373,354,374,375],"Cyclophosphamide","Dexamethasone","Lenalidomide",{"trials":377,"activeCount":52},[378],{"nctId":379,"briefTitle":380,"status":64,"phases":381,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":386},"NCT01910987","Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib",[44],"2016-02","2013-04",80,[20],[322,342,322,342],{"trials":388,"activeCount":52},[],{"trials":390,"activeCount":52},[],{"intervention":392,"totalTrials":11,"cells":393},"Telaprevir",{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":398,"PHASE3":400,"PHASE4":445,"NA":447},{"trials":395,"activeCount":52},[],{"trials":397,"activeCount":52},[],{"trials":399,"activeCount":52},[],{"trials":401,"activeCount":52},[402,414,425,434],{"nctId":403,"briefTitle":404,"status":64,"phases":405,"primaryCompletion":360,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":411},"NCT01571583","An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation",[44],"2014-07","2012-02",74,[410],"Chronic Hepatitis C Virus (HCV) Infection",[392,412,413],"Pegylated interferon alfa-2a","Ribavirin",{"nctId":415,"briefTitle":416,"status":64,"phases":417,"primaryCompletion":418,"completion":419,"start":420,"enrollment":370,"conditions":421,"interventions":423},"NCT01513941","An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)",[44],"2014-03","2014-06","2012-04",[422],"Chronic Hepatitis C",[392,413,424],"Pegylated-Interferon-alfa-2a",{"nctId":426,"briefTitle":427,"status":64,"phases":428,"primaryCompletion":429,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":433},"NCT01500616","Telaprevir Open-Label Study in Co-Infected Patients",[44],"2014-08","2012-06",122,[26],[392,392],{"nctId":435,"briefTitle":436,"status":64,"phases":437,"primaryCompletion":420,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":443},"NCT01498068","Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C",[44],"2013-03","2012-01",36,[442],"Genotype 1 Chronic Hepatitis C",[392,444,413],"Pegylated-interferon-alfa-2a",{"trials":446,"activeCount":52},[],{"trials":448,"activeCount":52},[],{"intervention":413,"totalTrials":11,"cells":450},{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":482,"NA":484},{"trials":452,"activeCount":52},[],{"trials":454,"activeCount":52},[],{"trials":456,"activeCount":52},[],{"trials":458,"activeCount":52},[459,463,467,471],{"nctId":403,"briefTitle":404,"status":64,"phases":460,"primaryCompletion":360,"completion":406,"start":407,"enrollment":408,"conditions":461,"interventions":462},[44],[410],[392,412,413],{"nctId":415,"briefTitle":416,"status":64,"phases":464,"primaryCompletion":418,"completion":419,"start":420,"enrollment":370,"conditions":465,"interventions":466},[44],[422],[392,413,424],{"nctId":435,"briefTitle":436,"status":64,"phases":468,"primaryCompletion":420,"completion":438,"start":439,"enrollment":440,"conditions":469,"interventions":470},[44],[442],[392,444,413],{"nctId":472,"briefTitle":473,"status":64,"phases":474,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":480},"NCT01846832","A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection",[44],"2015-08","2013-09",232,[26,479],"Infection",[481,412,413],"TMC435",{"trials":483,"activeCount":52},[],{"trials":485,"activeCount":52},[],{"intervention":342,"totalTrials":24,"cells":487},{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":492,"PHASE3":502,"PHASE4":508,"NA":510},{"trials":489,"activeCount":52},[],{"trials":491,"activeCount":52},[],{"trials":493,"activeCount":52},[494,498],{"nctId":332,"briefTitle":333,"status":334,"phases":495,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":496,"interventions":497},[43],[20],[341,322,342,343],{"nctId":366,"briefTitle":367,"status":64,"phases":499,"primaryCompletion":67,"completion":67,"start":369,"enrollment":370,"conditions":500,"interventions":501},[43],[20],[373,354,374,375],{"trials":503,"activeCount":52},[504],{"nctId":379,"briefTitle":380,"status":64,"phases":505,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":506,"interventions":507},[44],[20],[322,342,322,342],{"trials":509,"activeCount":52},[],{"trials":511,"activeCount":52},[],{"intervention":412,"totalTrials":29,"cells":513},{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":520,"PHASE4":530,"NA":532},{"trials":515,"activeCount":52},[],{"trials":517,"activeCount":52},[],{"trials":519,"activeCount":52},[],{"trials":521,"activeCount":52},[522,526],{"nctId":403,"briefTitle":404,"status":64,"phases":523,"primaryCompletion":360,"completion":406,"start":407,"enrollment":408,"conditions":524,"interventions":525},[44],[410],[392,412,413],{"nctId":472,"briefTitle":473,"status":64,"phases":527,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":528,"interventions":529},[44],[26,479],[481,412,413],{"trials":531,"activeCount":52},[],{"trials":533,"activeCount":52},[],{"intervention":424,"totalTrials":29,"cells":535},{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":552,"NA":554},{"trials":537,"activeCount":52},[],{"trials":539,"activeCount":52},[],{"trials":541,"activeCount":52},[],{"trials":543,"activeCount":52},[544,548],{"nctId":415,"briefTitle":416,"status":64,"phases":545,"primaryCompletion":418,"completion":419,"start":420,"enrollment":370,"conditions":546,"interventions":547},[44],[422],[392,413,424],{"nctId":435,"briefTitle":436,"status":64,"phases":549,"primaryCompletion":420,"completion":438,"start":439,"enrollment":440,"conditions":550,"interventions":551},[44],[442],[392,444,413],{"trials":553,"activeCount":52},[],{"trials":555,"activeCount":52},[],{"intervention":557,"totalTrials":29,"cells":558},"Darunavir",{"EARLY_PHASE1":559,"PHASE1":561,"PHASE2":563,"PHASE3":565,"PHASE4":594,"NA":596},{"trials":560,"activeCount":52},[],{"trials":562,"activeCount":52},[],{"trials":564,"activeCount":52},[],{"trials":566,"activeCount":52},[567,580],{"nctId":568,"briefTitle":569,"status":64,"phases":570,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":578},"NCT01448707","A Clinical Trial Comparing the Efficacy of Darunavir\u002FRitonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir\u002FRitonavir and 2 Nucleoside\u002FNucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment",[44],"2014-06-11","2015-03-18","2012-03-15",274,[576,577],"Human Immunodeficiency Virus (HIV) Infections","Acquired Immunodeficiency Syndrome (AIDS) Virus",[557,579],"Ritonavir",{"nctId":581,"briefTitle":582,"status":64,"phases":583,"primaryCompletion":348,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":592},"NCT00458302","Treatment Simplification by Darunavir\u002FRitonavir 800\u002F100 mg Once a Day Versus a Triple Combination Therapy With Darunavir\u002FRitonavir",[44],"2011-01","2007-06",256,[588,589,590,591],"HIV Infections","AIDS Virus","Human Immunodeficiency Virus","Acquired Immunodeficiency Syndrome Virus",[593,593],"darunavir",{"trials":595,"activeCount":52},[],{"trials":597,"activeCount":52},[],{"intervention":599,"totalTrials":29,"cells":600},"Esketamine 28 mg",{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":643,"NA":645},{"trials":602,"activeCount":52},[],{"trials":604,"activeCount":52},[],{"trials":606,"activeCount":52},[],{"trials":608,"activeCount":52},[609,628],{"nctId":610,"briefTitle":611,"status":612,"phases":613,"primaryCompletion":614,"completion":614,"start":615,"enrollment":52,"conditions":616,"interventions":618},"NCT03852160","A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression","WITHDRAWN",[44],"2021-07-25","2019-12-01",[617],"Depressive Disorder, Treatment-Resistant",[599,619,620,621,622,623,624,625,626,627],"Esketamine 56 mg","Esketamine 84 mg","Escitalopram","Sertraline","Duloxetine","Mirtazapine","Agomelatine","Bupropion","Trazodone Prolonged Release",{"nctId":629,"briefTitle":630,"status":64,"phases":631,"primaryCompletion":632,"completion":633,"start":634,"enrollment":635,"conditions":636,"interventions":638},"NCT04338321","A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor\u002FSerotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder",[44],"2022-01-20","2022-07-15","2020-08-21",676,[637],"Depressive Disorder, Major",[599,619,620,639,640,641,642],"Quetiapine XR 50 mg","Quetiapine XR 100 mg","Quetiapine XR 150 mg","SSRI\u002FSNRI",{"trials":644,"activeCount":52},[],{"trials":646,"activeCount":52},[],{"intervention":619,"totalTrials":29,"cells":648},{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":655,"PHASE4":665,"NA":667},{"trials":650,"activeCount":52},[],{"trials":652,"activeCount":52},[],{"trials":654,"activeCount":52},[],{"trials":656,"activeCount":52},[657,661],{"nctId":610,"briefTitle":611,"status":612,"phases":658,"primaryCompletion":614,"completion":614,"start":615,"enrollment":52,"conditions":659,"interventions":660},[44],[617],[599,619,620,621,622,623,624,625,626,627],{"nctId":629,"briefTitle":630,"status":64,"phases":662,"primaryCompletion":632,"completion":633,"start":634,"enrollment":635,"conditions":663,"interventions":664},[44],[637],[599,619,620,639,640,641,642],{"trials":666,"activeCount":52},[],{"trials":668,"activeCount":52},[],{"intervention":620,"totalTrials":29,"cells":670},{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":687,"NA":689},{"trials":672,"activeCount":52},[],{"trials":674,"activeCount":52},[],{"trials":676,"activeCount":52},[],{"trials":678,"activeCount":52},[679,683],{"nctId":610,"briefTitle":611,"status":612,"phases":680,"primaryCompletion":614,"completion":614,"start":615,"enrollment":52,"conditions":681,"interventions":682},[44],[617],[599,619,620,621,622,623,624,625,626,627],{"nctId":629,"briefTitle":630,"status":64,"phases":684,"primaryCompletion":632,"completion":633,"start":634,"enrollment":635,"conditions":685,"interventions":686},[44],[637],[599,619,620,639,640,641,642],{"trials":688,"activeCount":52},[],{"trials":690,"activeCount":52},[],{"intervention":692,"totalTrials":29,"cells":693},"efavirenz",{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":713,"PHASE4":730,"NA":732},{"trials":695,"activeCount":52},[],{"trials":697,"activeCount":52},[],{"trials":699,"activeCount":52},[700],{"nctId":701,"briefTitle":702,"status":64,"phases":703,"primaryCompletion":704,"completion":584,"start":705,"enrollment":706,"conditions":707,"interventions":711},"NCT00903682","A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside\u002FNucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients",[43],"2010-02","2009-06",157,[708,709,710],"HIV Infection","HIV","Acquired Immunodeficiency Syndrome",[712,692],"etravirine",{"trials":714,"activeCount":52},[715],{"nctId":716,"briefTitle":717,"status":64,"phases":718,"primaryCompletion":719,"completion":720,"start":721,"enrollment":722,"conditions":723,"interventions":725},"NCT01709084","A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate\u002FEmtricitabine\u002FRilpivirine (TDF\u002FFTC\u002FRPV) Versus TDF\u002FFTC\u002FEfavirenz (TDF\u002FFTC\u002FEFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment",[44],"2015-10-22","2020-07-02","2013-10-02",426,[724],"Human Immunodeficiency Virus-type 1 Infection",[726,727,728,729],"Rilpivirine","Efavirenz","Tenofovir disoproxil fumarate","Emtricitabine",{"trials":731,"activeCount":52},[],{"trials":733,"activeCount":52},[],{"intervention":735,"totalTrials":29,"cells":736},"Paliperidone ER",{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":766,"NA":768},{"trials":738,"activeCount":52},[],{"trials":740,"activeCount":52},[],{"trials":742,"activeCount":52},[],{"trials":744,"activeCount":52},[745,755],{"nctId":746,"briefTitle":747,"status":64,"phases":748,"primaryCompletion":749,"completion":750,"start":751,"enrollment":752,"conditions":753,"interventions":754},"NCT00460512","An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia",[44],"2009-01-22","2020-03-04","2007-04-25",1814,[17],[735],{"nctId":756,"briefTitle":757,"status":64,"phases":758,"primaryCompletion":759,"completion":759,"start":760,"enrollment":761,"conditions":762,"interventions":763},"NCT00645099","A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia",[44],"2009-04","2007-10",462,[17],[764,765],"olanzapine","paliperidone ER",{"trials":767,"activeCount":52},[],{"trials":769,"activeCount":52},[],{"intervention":771,"totalTrials":29,"cells":772},"Paliperidone Palmitate",{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":779,"PHASE4":799,"NA":801},{"trials":774,"activeCount":52},[],{"trials":776,"activeCount":52},[],{"trials":778,"activeCount":52},[],{"trials":780,"activeCount":52},[781,789],{"nctId":782,"briefTitle":783,"status":64,"phases":784,"primaryCompletion":359,"completion":785,"start":66,"enrollment":786,"conditions":787,"interventions":788},"NCT01281527","Paliperidone Palmitate Flexible Dosing in Schizophrenia",[44],"2013-11",1044,[17],[771],{"nctId":790,"briefTitle":791,"status":64,"phases":792,"primaryCompletion":793,"completion":793,"start":704,"enrollment":794,"conditions":795,"interventions":796},"NCT01081769","Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics",[44],"2013-02",769,[17],[797,798],"paliperidone palmitate","oral antipsychotics",{"trials":800,"activeCount":52},[],{"trials":802,"activeCount":52},[],{"intervention":804,"totalTrials":8,"cells":805},"Paliperidone",{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":812,"PHASE4":823,"NA":825},{"trials":807,"activeCount":52},[],{"trials":809,"activeCount":52},[],{"trials":811,"activeCount":52},[],{"trials":813,"activeCount":52},[814],{"nctId":815,"briefTitle":816,"status":64,"phases":817,"primaryCompletion":369,"completion":818,"start":819,"enrollment":820,"conditions":821,"interventions":822},"NCT00566631","An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia",[44],"2009-05","2007-07",294,[17],[804],{"trials":824,"activeCount":52},[],{"trials":826,"activeCount":52},[],{"intervention":828,"totalTrials":8,"cells":829},"Tapentadol IR 50 mg",{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":849,"NA":851},{"trials":831,"activeCount":52},[],{"trials":833,"activeCount":52},[],{"trials":835,"activeCount":52},[],{"trials":837,"activeCount":52},[838],{"nctId":839,"briefTitle":840,"status":64,"phases":841,"primaryCompletion":842,"completion":842,"start":843,"enrollment":844,"conditions":845,"interventions":847},"NCT01813890","A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo",[44],"2014-01","2013-01",60,[846],"Hallux Valgus",[828,848],"Tapentadol IR 75 mg",{"trials":850,"activeCount":52},[],{"trials":852,"activeCount":52},[],{"intervention":848,"totalTrials":8,"cells":854},{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":861,"PHASE4":867,"NA":869},{"trials":856,"activeCount":52},[],{"trials":858,"activeCount":52},[],{"trials":860,"activeCount":52},[],{"trials":862,"activeCount":52},[863],{"nctId":839,"briefTitle":840,"status":64,"phases":864,"primaryCompletion":842,"completion":842,"start":843,"enrollment":844,"conditions":865,"interventions":866},[44],[846],[828,848],{"trials":868,"activeCount":52},[],{"trials":870,"activeCount":52},[],{"intervention":872,"totalTrials":8,"cells":873},"Group 2: Placebo",{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":878,"PHASE3":880,"PHASE4":893,"NA":895},{"trials":875,"activeCount":52},[],{"trials":877,"activeCount":52},[],{"trials":879,"activeCount":52},[],{"trials":881,"activeCount":52},[882],{"nctId":883,"briefTitle":884,"status":64,"phases":885,"primaryCompletion":886,"completion":887,"start":888,"enrollment":351,"conditions":889,"interventions":891},"NCT01381809","An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes",[44],"2015-01","2016-01","2011-10",[890],"Myelodysplastic Syndromes",[872,892],"Group 1: Epoetin alfa",{"trials":894,"activeCount":52},[],{"trials":896,"activeCount":52},[],{"intervention":892,"totalTrials":8,"cells":898},{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":903,"PHASE3":905,"PHASE4":911,"NA":913},{"trials":900,"activeCount":52},[],{"trials":902,"activeCount":52},[],{"trials":904,"activeCount":52},[],{"trials":906,"activeCount":52},[907],{"nctId":883,"briefTitle":884,"status":64,"phases":908,"primaryCompletion":886,"completion":887,"start":888,"enrollment":351,"conditions":909,"interventions":910},[44],[890],[872,892],{"trials":912,"activeCount":52},[],{"trials":914,"activeCount":52},[],{"intervention":916,"totalTrials":8,"cells":917},"Aripiprazole",{"EARLY_PHASE1":918,"PHASE1":920,"PHASE2":922,"PHASE3":924,"PHASE4":938,"NA":940},{"trials":919,"activeCount":52},[],{"trials":921,"activeCount":52},[],{"trials":923,"activeCount":52},[],{"trials":925,"activeCount":52},[926],{"nctId":927,"briefTitle":928,"status":64,"phases":929,"primaryCompletion":930,"completion":930,"start":931,"enrollment":932,"conditions":933,"interventions":935},"NCT00216476","A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder",[44],"2007-11","2004-10",753,[17,934],"Psychotic Disorders",[916,936,937],"Risperidone Long Acting Injectable","Quetiapine",{"trials":939,"activeCount":52},[],{"trials":941,"activeCount":52},[],{"intervention":936,"totalTrials":8,"cells":943},{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":950,"PHASE4":956,"NA":958},{"trials":945,"activeCount":52},[],{"trials":947,"activeCount":52},[],{"trials":949,"activeCount":52},[],{"trials":951,"activeCount":52},[952],{"nctId":927,"briefTitle":928,"status":64,"phases":953,"primaryCompletion":930,"completion":930,"start":931,"enrollment":932,"conditions":954,"interventions":955},[44],[17,934],[916,936,937],{"trials":957,"activeCount":52},[],{"trials":959,"activeCount":52},[],{"intervention":937,"totalTrials":8,"cells":961},{"EARLY_PHASE1":962,"PHASE1":964,"PHASE2":966,"PHASE3":968,"PHASE4":974,"NA":976},{"trials":963,"activeCount":52},[],{"trials":965,"activeCount":52},[],{"trials":967,"activeCount":52},[],{"trials":969,"activeCount":52},[970],{"nctId":927,"briefTitle":928,"status":64,"phases":971,"primaryCompletion":930,"completion":930,"start":931,"enrollment":932,"conditions":972,"interventions":973},[44],[17,934],[916,936,937],{"trials":975,"activeCount":52},[],{"trials":977,"activeCount":52},[],{"intervention":979,"totalTrials":8,"cells":980},"Domperidone",{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":985,"PHASE3":987,"PHASE4":999,"NA":1001},{"trials":982,"activeCount":52},[],{"trials":984,"activeCount":52},[],{"trials":986,"activeCount":52},[],{"trials":988,"activeCount":52},[989],{"nctId":990,"briefTitle":991,"status":334,"phases":992,"primaryCompletion":993,"completion":993,"start":994,"enrollment":995,"conditions":996,"interventions":998},"NCT02699385","A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis",[44],"2017-08-03","2015-12-07",10,[997],"Gastroenteritis",[979],{"trials":1000,"activeCount":52},[],{"trials":1002,"activeCount":52},[],{"intervention":1004,"totalTrials":8,"cells":1005},"prolonged release (PR) OROS methylphenidate 54 mg",{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1012,"PHASE4":1024,"NA":1026},{"trials":1007,"activeCount":52},[],{"trials":1009,"activeCount":52},[],{"trials":1011,"activeCount":52},[],{"trials":1013,"activeCount":52},[1014],{"nctId":1015,"briefTitle":1016,"status":64,"phases":1017,"primaryCompletion":759,"completion":759,"start":1018,"enrollment":1019,"conditions":1020,"interventions":1022},"NCT00714688","A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder",[44],"2008-02",279,[1021],"Attention Deficit\u002F Hyperactivity Disorder",[1004,1023],"prolonged release (PR) OROS methylphenidate 72 mg",{"trials":1025,"activeCount":52},[],{"trials":1027,"activeCount":52},[],{"intervention":1023,"totalTrials":8,"cells":1029},{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1036,"PHASE4":1042,"NA":1044},{"trials":1031,"activeCount":52},[],{"trials":1033,"activeCount":52},[],{"trials":1035,"activeCount":52},[],{"trials":1037,"activeCount":52},[1038],{"nctId":1015,"briefTitle":1016,"status":64,"phases":1039,"primaryCompletion":759,"completion":759,"start":1018,"enrollment":1019,"conditions":1040,"interventions":1041},[44],[1021],[1004,1023],{"trials":1043,"activeCount":52},[],{"trials":1045,"activeCount":52},[],{"intervention":579,"totalTrials":8,"cells":1047},{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1054,"PHASE4":1060,"NA":1062},{"trials":1049,"activeCount":52},[],{"trials":1051,"activeCount":52},[],{"trials":1053,"activeCount":52},[],{"trials":1055,"activeCount":52},[1056],{"nctId":568,"briefTitle":569,"status":64,"phases":1057,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":1058,"interventions":1059},[44],[576,577],[557,579],{"trials":1061,"activeCount":52},[],{"trials":1063,"activeCount":52},[],{"intervention":621,"totalTrials":8,"cells":1065},{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1070,"PHASE3":1072,"PHASE4":1078,"NA":1080},{"trials":1067,"activeCount":52},[],{"trials":1069,"activeCount":52},[],{"trials":1071,"activeCount":52},[],{"trials":1073,"activeCount":52},[1074],{"nctId":610,"briefTitle":611,"status":612,"phases":1075,"primaryCompletion":614,"completion":614,"start":615,"enrollment":52,"conditions":1076,"interventions":1077},[44],[617],[599,619,620,621,622,623,624,625,626,627],{"trials":1079,"activeCount":52},[],{"trials":1081,"activeCount":52},[],{"intervention":622,"totalTrials":8,"cells":1083},{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1090,"PHASE4":1096,"NA":1098},{"trials":1085,"activeCount":52},[],{"trials":1087,"activeCount":52},[],{"trials":1089,"activeCount":52},[],{"trials":1091,"activeCount":52},[1092],{"nctId":610,"briefTitle":611,"status":612,"phases":1093,"primaryCompletion":614,"completion":614,"start":615,"enrollment":52,"conditions":1094,"interventions":1095},[44],[617],[599,619,620,621,622,623,624,625,626,627],{"trials":1097,"activeCount":52},[],{"trials":1099,"activeCount":52},[],{"intervention":623,"totalTrials":8,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1114,"NA":1116},{"trials":1103,"activeCount":52},[],{"trials":1105,"activeCount":52},[],{"trials":1107,"activeCount":52},[],{"trials":1109,"activeCount":52},[1110],{"nctId":610,"briefTitle":611,"status":612,"phases":1111,"primaryCompletion":614,"completion":614,"start":615,"enrollment":52,"conditions":1112,"interventions":1113},[44],[617],[599,619,620,621,622,623,624,625,626,627],{"trials":1115,"activeCount":52},[],{"trials":1117,"activeCount":52},[],{"intervention":624,"totalTrials":8,"cells":1119},{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1126,"PHASE4":1132,"NA":1134},{"trials":1121,"activeCount":52},[],{"trials":1123,"activeCount":52},[],{"trials":1125,"activeCount":52},[],{"trials":1127,"activeCount":52},[1128],{"nctId":610,"briefTitle":611,"status":612,"phases":1129,"primaryCompletion":614,"completion":614,"start":615,"enrollment":52,"conditions":1130,"interventions":1131},[44],[617],[599,619,620,621,622,623,624,625,626,627],{"trials":1133,"activeCount":52},[],{"trials":1135,"activeCount":52},[],{"intervention":625,"totalTrials":8,"cells":1137},{"EARLY_PHASE1":1138,"PHASE1":1140,"PHASE2":1142,"PHASE3":1144,"PHASE4":1150,"NA":1152},{"trials":1139,"activeCount":52},[],{"trials":1141,"activeCount":52},[],{"trials":1143,"activeCount":52},[],{"trials":1145,"activeCount":52},[1146],{"nctId":610,"briefTitle":611,"status":612,"phases":1147,"primaryCompletion":614,"completion":614,"start":615,"enrollment":52,"conditions":1148,"interventions":1149},[44],[617],[599,619,620,621,622,623,624,625,626,627],{"trials":1151,"activeCount":52},[],{"trials":1153,"activeCount":52},[],{"intervention":626,"totalTrials":8,"cells":1155},{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1162,"PHASE4":1168,"NA":1170},{"trials":1157,"activeCount":52},[],{"trials":1159,"activeCount":52},[],{"trials":1161,"activeCount":52},[],{"trials":1163,"activeCount":52},[1164],{"nctId":610,"briefTitle":611,"status":612,"phases":1165,"primaryCompletion":614,"completion":614,"start":615,"enrollment":52,"conditions":1166,"interventions":1167},[44],[617],[599,619,620,621,622,623,624,625,626,627],{"trials":1169,"activeCount":52},[],{"trials":1171,"activeCount":52},[],{"intervention":627,"totalTrials":8,"cells":1173},{"EARLY_PHASE1":1174,"PHASE1":1176,"PHASE2":1178,"PHASE3":1180,"PHASE4":1186,"NA":1188},{"trials":1175,"activeCount":52},[],{"trials":1177,"activeCount":52},[],{"trials":1179,"activeCount":52},[],{"trials":1181,"activeCount":52},[1182],{"nctId":610,"briefTitle":611,"status":612,"phases":1183,"primaryCompletion":614,"completion":614,"start":615,"enrollment":52,"conditions":1184,"interventions":1185},[44],[617],[599,619,620,621,622,623,624,625,626,627],{"trials":1187,"activeCount":52},[],{"trials":1189,"activeCount":52},[],{"intervention":726,"totalTrials":8,"cells":1191},{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1196,"PHASE3":1198,"PHASE4":1204,"NA":1206},{"trials":1193,"activeCount":52},[],{"trials":1195,"activeCount":52},[],{"trials":1197,"activeCount":52},[],{"trials":1199,"activeCount":52},[1200],{"nctId":716,"briefTitle":717,"status":64,"phases":1201,"primaryCompletion":719,"completion":720,"start":721,"enrollment":722,"conditions":1202,"interventions":1203},[44],[724],[726,727,728,729],{"trials":1205,"activeCount":52},[],{"trials":1207,"activeCount":52},[],{"intervention":728,"totalTrials":8,"cells":1209},{"EARLY_PHASE1":1210,"PHASE1":1212,"PHASE2":1214,"PHASE3":1216,"PHASE4":1222,"NA":1224},{"trials":1211,"activeCount":52},[],{"trials":1213,"activeCount":52},[],{"trials":1215,"activeCount":52},[],{"trials":1217,"activeCount":52},[1218],{"nctId":716,"briefTitle":717,"status":64,"phases":1219,"primaryCompletion":719,"completion":720,"start":721,"enrollment":722,"conditions":1220,"interventions":1221},[44],[724],[726,727,728,729],{"trials":1223,"activeCount":52},[],{"trials":1225,"activeCount":52},[],{"intervention":729,"totalTrials":8,"cells":1227},{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1234,"PHASE4":1240,"NA":1242},{"trials":1229,"activeCount":52},[],{"trials":1231,"activeCount":52},[],{"trials":1233,"activeCount":52},[],{"trials":1235,"activeCount":52},[1236],{"nctId":716,"briefTitle":717,"status":64,"phases":1237,"primaryCompletion":719,"completion":720,"start":721,"enrollment":722,"conditions":1238,"interventions":1239},[44],[724],[726,727,728,729],{"trials":1241,"activeCount":52},[],{"trials":1243,"activeCount":52},[],{"intervention":639,"totalTrials":8,"cells":1245},{"EARLY_PHASE1":1246,"PHASE1":1248,"PHASE2":1250,"PHASE3":1252,"PHASE4":1258,"NA":1260},{"trials":1247,"activeCount":52},[],{"trials":1249,"activeCount":52},[],{"trials":1251,"activeCount":52},[],{"trials":1253,"activeCount":52},[1254],{"nctId":629,"briefTitle":630,"status":64,"phases":1255,"primaryCompletion":632,"completion":633,"start":634,"enrollment":635,"conditions":1256,"interventions":1257},[44],[637],[599,619,620,639,640,641,642],{"trials":1259,"activeCount":52},[],{"trials":1261,"activeCount":52},[],{"intervention":640,"totalTrials":8,"cells":1263},{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1270,"PHASE4":1276,"NA":1278},{"trials":1265,"activeCount":52},[],{"trials":1267,"activeCount":52},[],{"trials":1269,"activeCount":52},[],{"trials":1271,"activeCount":52},[1272],{"nctId":629,"briefTitle":630,"status":64,"phases":1273,"primaryCompletion":632,"completion":633,"start":634,"enrollment":635,"conditions":1274,"interventions":1275},[44],[637],[599,619,620,639,640,641,642],{"trials":1277,"activeCount":52},[],{"trials":1279,"activeCount":52},[],{"intervention":641,"totalTrials":8,"cells":1281},{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1288,"PHASE4":1294,"NA":1296},{"trials":1283,"activeCount":52},[],{"trials":1285,"activeCount":52},[],{"trials":1287,"activeCount":52},[],{"trials":1289,"activeCount":52},[1290],{"nctId":629,"briefTitle":630,"status":64,"phases":1291,"primaryCompletion":632,"completion":633,"start":634,"enrollment":635,"conditions":1292,"interventions":1293},[44],[637],[599,619,620,639,640,641,642],{"trials":1295,"activeCount":52},[],{"trials":1297,"activeCount":52},[],{"intervention":642,"totalTrials":8,"cells":1299},{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1306,"PHASE4":1312,"NA":1314},{"trials":1301,"activeCount":52},[],{"trials":1303,"activeCount":52},[],{"trials":1305,"activeCount":52},[],{"trials":1307,"activeCount":52},[1308],{"nctId":629,"briefTitle":630,"status":64,"phases":1309,"primaryCompletion":632,"completion":633,"start":634,"enrollment":635,"conditions":1310,"interventions":1311},[44],[637],[599,619,620,639,640,641,642],{"trials":1313,"activeCount":52},[],{"trials":1315,"activeCount":52},[],{"intervention":481,"totalTrials":8,"cells":1317},{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1324,"PHASE4":1330,"NA":1332},{"trials":1319,"activeCount":52},[],{"trials":1321,"activeCount":52},[],{"trials":1323,"activeCount":52},[],{"trials":1325,"activeCount":52},[1326],{"nctId":472,"briefTitle":473,"status":64,"phases":1327,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":1328,"interventions":1329},[44],[26,479],[481,412,413],{"trials":1331,"activeCount":52},[],{"trials":1333,"activeCount":52},[],{"intervention":1335,"totalTrials":8,"cells":1336},"double blind placebo",{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1343,"PHASE4":1357,"NA":1359},{"trials":1338,"activeCount":52},[],{"trials":1340,"activeCount":52},[],{"trials":1342,"activeCount":52},[],{"trials":1344,"activeCount":52},[1345],{"nctId":1346,"briefTitle":1347,"status":64,"phases":1348,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1352,"interventions":1354},"NCT00307684","Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)",[44],"2008-07","2006-01",155,[1353],"Attention Deficit Disorder With Hyperactivity",[1335,1355,1356],"double blind PR OROS methylphenidate","open label PR OROS methylphenidate",{"trials":1358,"activeCount":52},[],{"trials":1360,"activeCount":52},[],{"intervention":1355,"totalTrials":8,"cells":1362},{"EARLY_PHASE1":1363,"PHASE1":1365,"PHASE2":1367,"PHASE3":1369,"PHASE4":1375,"NA":1377},{"trials":1364,"activeCount":52},[],{"trials":1366,"activeCount":52},[],{"trials":1368,"activeCount":52},[],{"trials":1370,"activeCount":52},[1371],{"nctId":1346,"briefTitle":1347,"status":64,"phases":1372,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1373,"interventions":1374},[44],[1353],[1335,1355,1356],{"trials":1376,"activeCount":52},[],{"trials":1378,"activeCount":52},[],{"intervention":1356,"totalTrials":8,"cells":1380},{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1387,"PHASE4":1393,"NA":1395},{"trials":1382,"activeCount":52},[],{"trials":1384,"activeCount":52},[],{"trials":1386,"activeCount":52},[],{"trials":1388,"activeCount":52},[1389],{"nctId":1346,"briefTitle":1347,"status":64,"phases":1390,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1391,"interventions":1392},[44],[1353],[1335,1355,1356],{"trials":1394,"activeCount":52},[],{"trials":1396,"activeCount":52},[],{"intervention":1398,"totalTrials":8,"cells":1399},"OROS hydromorphone HCl",{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1404,"PHASE3":1406,"PHASE4":1418,"NA":1420},{"trials":1401,"activeCount":52},[],{"trials":1403,"activeCount":52},[],{"trials":1405,"activeCount":52},[],{"trials":1407,"activeCount":52},[1408],{"nctId":1409,"briefTitle":1410,"status":64,"phases":1411,"primaryCompletion":1412,"completion":1412,"start":760,"enrollment":1413,"conditions":1414,"interventions":1417},"NCT00980798","Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee",[44],"2008-11",288,[31,1415,1416],"Osteoarthritis, Hip","Osteoarthritis, Knee",[1398],{"trials":1419,"activeCount":52},[],{"trials":1421,"activeCount":52},[],{"intervention":764,"totalTrials":8,"cells":1423},{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1430,"PHASE4":1436,"NA":1438},{"trials":1425,"activeCount":52},[],{"trials":1427,"activeCount":52},[],{"trials":1429,"activeCount":52},[],{"trials":1431,"activeCount":52},[1432],{"nctId":756,"briefTitle":757,"status":64,"phases":1433,"primaryCompletion":759,"completion":759,"start":760,"enrollment":761,"conditions":1434,"interventions":1435},[44],[17],[764,765],{"trials":1437,"activeCount":52},[],{"trials":1439,"activeCount":52},[],{"intervention":1441,"totalTrials":8,"cells":1442},"Guselkumab",{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1449,"PHASE4":1461,"NA":1463},{"trials":1444,"activeCount":52},[],{"trials":1446,"activeCount":52},[],{"trials":1448,"activeCount":52},[],{"trials":1450,"activeCount":52},[1451],{"nctId":1452,"briefTitle":1453,"status":64,"phases":1454,"primaryCompletion":1455,"completion":1456,"start":1457,"enrollment":1458,"conditions":1459,"interventions":1460},"NCT03818035","A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis",[44],"2022-03-07","2025-01-07","2019-02-08",880,[23],[1441],{"trials":1462,"activeCount":52},[],{"trials":1464,"activeCount":52},[],{"intervention":798,"totalTrials":8,"cells":1466},{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1473,"PHASE4":1479,"NA":1481},{"trials":1468,"activeCount":52},[],{"trials":1470,"activeCount":52},[],{"trials":1472,"activeCount":52},[],{"trials":1474,"activeCount":52},[1475],{"nctId":790,"briefTitle":791,"status":64,"phases":1476,"primaryCompletion":793,"completion":793,"start":704,"enrollment":794,"conditions":1477,"interventions":1478},[44],[17],[797,798],{"trials":1480,"activeCount":52},[],{"trials":1482,"activeCount":52},[],{"intervention":1484,"totalTrials":29,"cells":1485},"Simeprevir",{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1510,"PHASE4":1512,"NA":1514},{"trials":1487,"activeCount":52},[],{"trials":1489,"activeCount":52},[],{"trials":1491,"activeCount":52},[1492,1502],{"nctId":1493,"briefTitle":1494,"status":64,"phases":1495,"primaryCompletion":1496,"completion":1496,"start":1497,"enrollment":1498,"conditions":1499,"interventions":1500},"NCT02278419","An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection",[43],"2015-10","2014-12",63,[28],[1484,1501],"Sofosbuvir",{"nctId":1503,"briefTitle":1504,"status":64,"phases":1505,"primaryCompletion":887,"completion":1506,"start":886,"enrollment":362,"conditions":1507,"interventions":1508},"NCT02268864","A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants",[43],"2016-04",[26],[1484,1509],"Daclatasvir",{"trials":1511,"activeCount":52},[],{"trials":1513,"activeCount":52},[],{"trials":1515,"activeCount":52},[],{"intervention":341,"totalTrials":8,"cells":1517},{"EARLY_PHASE1":1518,"PHASE1":1520,"PHASE2":1522,"PHASE3":1528,"PHASE4":1530,"NA":1532},{"trials":1519,"activeCount":52},[],{"trials":1521,"activeCount":52},[],{"trials":1523,"activeCount":52},[1524],{"nctId":332,"briefTitle":333,"status":334,"phases":1525,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":1526,"interventions":1527},[43],[20],[341,322,342,343],{"trials":1529,"activeCount":52},[],{"trials":1531,"activeCount":52},[],{"trials":1533,"activeCount":52},[],{"intervention":343,"totalTrials":8,"cells":1535},{"EARLY_PHASE1":1536,"PHASE1":1538,"PHASE2":1540,"PHASE3":1546,"PHASE4":1548,"NA":1550},{"trials":1537,"activeCount":52},[],{"trials":1539,"activeCount":52},[],{"trials":1541,"activeCount":52},[1542],{"nctId":332,"briefTitle":333,"status":334,"phases":1543,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":1544,"interventions":1545},[43],[20],[341,322,342,343],{"trials":1547,"activeCount":52},[],{"trials":1549,"activeCount":52},[],{"trials":1551,"activeCount":52},[],{"intervention":1501,"totalTrials":8,"cells":1553},{"EARLY_PHASE1":1554,"PHASE1":1556,"PHASE2":1558,"PHASE3":1564,"PHASE4":1566,"NA":1568},{"trials":1555,"activeCount":52},[],{"trials":1557,"activeCount":52},[],{"trials":1559,"activeCount":52},[1560],{"nctId":1493,"briefTitle":1494,"status":64,"phases":1561,"primaryCompletion":1496,"completion":1496,"start":1497,"enrollment":1498,"conditions":1562,"interventions":1563},[43],[28],[1484,1501],{"trials":1565,"activeCount":52},[],{"trials":1567,"activeCount":52},[],{"trials":1569,"activeCount":52},[],{"intervention":712,"totalTrials":8,"cells":1571},{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1576,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1573,"activeCount":52},[],{"trials":1575,"activeCount":52},[],{"trials":1577,"activeCount":52},[1578],{"nctId":701,"briefTitle":702,"status":64,"phases":1579,"primaryCompletion":704,"completion":584,"start":705,"enrollment":706,"conditions":1580,"interventions":1581},[43],[708,709,710],[712,692],{"trials":1583,"activeCount":52},[],{"trials":1585,"activeCount":52},[],{"trials":1587,"activeCount":52},[],{"intervention":1509,"totalTrials":8,"cells":1589},{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1594,"PHASE3":1600,"PHASE4":1602,"NA":1604},{"trials":1591,"activeCount":52},[],{"trials":1593,"activeCount":52},[],{"trials":1595,"activeCount":52},[1596],{"nctId":1503,"briefTitle":1504,"status":64,"phases":1597,"primaryCompletion":887,"completion":1506,"start":886,"enrollment":362,"conditions":1598,"interventions":1599},[43],[26],[1484,1509],{"trials":1601,"activeCount":52},[],{"trials":1603,"activeCount":52},[],{"trials":1605,"activeCount":52},[],{"intervention":373,"totalTrials":8,"cells":1607},{"EARLY_PHASE1":1608,"PHASE1":1610,"PHASE2":1612,"PHASE3":1618,"PHASE4":1620,"NA":1622},{"trials":1609,"activeCount":52},[],{"trials":1611,"activeCount":52},[],{"trials":1613,"activeCount":52},[1614],{"nctId":366,"briefTitle":367,"status":64,"phases":1615,"primaryCompletion":67,"completion":67,"start":369,"enrollment":370,"conditions":1616,"interventions":1617},[43],[20],[373,354,374,375],{"trials":1619,"activeCount":52},[],{"trials":1621,"activeCount":52},[],{"trials":1623,"activeCount":52},[],{"intervention":375,"totalTrials":8,"cells":1625},{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1636,"PHASE4":1638,"NA":1640},{"trials":1627,"activeCount":52},[],{"trials":1629,"activeCount":52},[],{"trials":1631,"activeCount":52},[1632],{"nctId":366,"briefTitle":367,"status":64,"phases":1633,"primaryCompletion":67,"completion":67,"start":369,"enrollment":370,"conditions":1634,"interventions":1635},[43],[20],[373,354,374,375],{"trials":1637,"activeCount":52},[],{"trials":1639,"activeCount":52},[],{"trials":1641,"activeCount":52},[],{"intervention":1643,"totalTrials":24,"cells":1644},"Pimodivir",{"EARLY_PHASE1":1645,"PHASE1":1647,"PHASE2":1679,"PHASE3":1681,"PHASE4":1683,"NA":1685},{"trials":1646,"activeCount":52},[],{"trials":1648,"activeCount":52},[1649,1658,1669],{"nctId":1650,"briefTitle":1651,"status":334,"phases":1652,"primaryCompletion":1653,"completion":1653,"start":1654,"enrollment":1655,"conditions":1656,"interventions":1657},"NCT03947814","A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment",[42],"2020-09-09","2019-07-02",29,[33],[1643],{"nctId":1659,"briefTitle":1660,"status":64,"phases":1661,"primaryCompletion":1662,"completion":1663,"start":1664,"enrollment":1665,"conditions":1666,"interventions":1667},"NCT03768609","A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults",[42],"2019-03-06","2019-03-12","2018-12-06",18,[14],[1643,1668],"Cyclosporine",{"nctId":1670,"briefTitle":1671,"status":64,"phases":1672,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":1675,"conditions":1676,"interventions":1678},"NCT03816631","A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment",[42],"2020-04-27","2019-05-28",42,[1677],"Hepatic Impairment",[1643],{"trials":1680,"activeCount":52},[],{"trials":1682,"activeCount":52},[],{"trials":1684,"activeCount":52},[],{"trials":1686,"activeCount":52},[],{"intervention":1688,"totalTrials":24,"cells":1689},"JNJ-42847922",{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1722,"PHASE3":1724,"PHASE4":1726,"NA":1728},{"trials":1691,"activeCount":52},[],{"trials":1693,"activeCount":52},[1694,1702,1713],{"nctId":1695,"briefTitle":1696,"status":64,"phases":1697,"primaryCompletion":382,"completion":382,"start":1698,"enrollment":440,"conditions":1699,"interventions":1700},"NCT02578472","Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants",[42],"2015-11",[14],[1688,1701],"Zolpidem",{"nctId":1703,"briefTitle":1704,"status":64,"phases":1705,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":1708,"conditions":1709,"interventions":1711},"NCT02476058","A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder",[42],"2016-01-04","2015-06-11",48,[1710],"Major Depressive Disorder",[1688,1712],"Diphenhydramine",{"nctId":1714,"briefTitle":1715,"status":64,"phases":1716,"primaryCompletion":1717,"completion":1717,"start":1718,"enrollment":9,"conditions":1719,"interventions":1720},"NCT03249402","A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants",[42],"2017-11-24","2017-08-14",[14],[1721,1688],"Ethinyl Estradiol + Levonorgestrel",{"trials":1723,"activeCount":52},[],{"trials":1725,"activeCount":52},[],{"trials":1727,"activeCount":52},[],{"trials":1729,"activeCount":52},[],{"intervention":1731,"totalTrials":29,"cells":1732},"JNJ-63623872",{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1757,"PHASE3":1759,"PHASE4":1761,"NA":1763},{"trials":1734,"activeCount":52},[],{"trials":1736,"activeCount":52},[1737,1747],{"nctId":1738,"briefTitle":1739,"status":64,"phases":1740,"primaryCompletion":1741,"completion":1742,"start":1743,"enrollment":1744,"conditions":1745,"interventions":1746},"NCT02860806","Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults",[42],"2017-06-06","2017-06-10","2016-08-08",66,[14],[1731],{"nctId":1748,"briefTitle":1749,"status":64,"phases":1750,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":1753,"conditions":1754,"interventions":1755},"NCT03023852","A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872\u002FOseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants",[42],"2017-04-14","2017-02-14",45,[14],[1731,1756],"Oseltamivir",{"trials":1758,"activeCount":52},[],{"trials":1760,"activeCount":52},[],{"trials":1762,"activeCount":52},[],{"trials":1764,"activeCount":52},[],{"intervention":1766,"totalTrials":29,"cells":1767},"JNJ-54175446",{"EARLY_PHASE1":1768,"PHASE1":1770,"PHASE2":1792,"PHASE3":1794,"PHASE4":1796,"NA":1798},{"trials":1769,"activeCount":52},[],{"trials":1771,"activeCount":52},[1772,1782],{"nctId":1773,"briefTitle":1774,"status":64,"phases":1775,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":1778,"conditions":1779,"interventions":1780},"NCT03088644","A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739",[42],"2017-11-14","2017-03-24",16,[14],[1766,1781],"18F-JNJ-64413739",{"nctId":1783,"briefTitle":1784,"status":64,"phases":1785,"primaryCompletion":1786,"completion":1786,"start":475,"enrollment":1787,"conditions":1788,"interventions":1789},"NCT02515955","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants",[42],"2016-03",76,[14],[1766,1790,1791],"Minocycline","D Amphetamine",{"trials":1793,"activeCount":52},[],{"trials":1795,"activeCount":52},[],{"trials":1797,"activeCount":52},[],{"trials":1799,"activeCount":52},[],{"intervention":1801,"totalTrials":8,"cells":1802},"JNJ-64041575",{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1816,"PHASE3":1818,"PHASE4":1820,"NA":1822},{"trials":1804,"activeCount":52},[],{"trials":1806,"activeCount":52},[1807],{"nctId":1808,"briefTitle":1809,"status":64,"phases":1810,"primaryCompletion":1811,"completion":1811,"start":1812,"enrollment":1665,"conditions":1813,"interventions":1814},"NCT03105986","A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults",[42],"2017-06-16","2017-04-05",[14],[1801,1815],"Probenecid",{"trials":1817,"activeCount":52},[],{"trials":1819,"activeCount":52},[],{"trials":1821,"activeCount":52},[],{"trials":1823,"activeCount":52},[],{"intervention":1815,"totalTrials":8,"cells":1825},{"EARLY_PHASE1":1826,"PHASE1":1828,"PHASE2":1834,"PHASE3":1836,"PHASE4":1838,"NA":1840},{"trials":1827,"activeCount":52},[],{"trials":1829,"activeCount":52},[1830],{"nctId":1808,"briefTitle":1809,"status":64,"phases":1831,"primaryCompletion":1811,"completion":1811,"start":1812,"enrollment":1665,"conditions":1832,"interventions":1833},[42],[14],[1801,1815],{"trials":1835,"activeCount":52},[],{"trials":1837,"activeCount":52},[],{"trials":1839,"activeCount":52},[],{"trials":1841,"activeCount":52},[],{"intervention":1701,"totalTrials":8,"cells":1843},{"EARLY_PHASE1":1844,"PHASE1":1846,"PHASE2":1852,"PHASE3":1854,"PHASE4":1856,"NA":1858},{"trials":1845,"activeCount":52},[],{"trials":1847,"activeCount":52},[1848],{"nctId":1695,"briefTitle":1696,"status":64,"phases":1849,"primaryCompletion":382,"completion":382,"start":1698,"enrollment":440,"conditions":1850,"interventions":1851},[42],[14],[1688,1701],{"trials":1853,"activeCount":52},[],{"trials":1855,"activeCount":52},[],{"trials":1857,"activeCount":52},[],{"trials":1859,"activeCount":52},[],{"intervention":1781,"totalTrials":8,"cells":1861},{"EARLY_PHASE1":1862,"PHASE1":1864,"PHASE2":1870,"PHASE3":1872,"PHASE4":1874,"NA":1876},{"trials":1863,"activeCount":52},[],{"trials":1865,"activeCount":52},[1866],{"nctId":1773,"briefTitle":1774,"status":64,"phases":1867,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":1778,"conditions":1868,"interventions":1869},[42],[14],[1766,1781],{"trials":1871,"activeCount":52},[],{"trials":1873,"activeCount":52},[],{"trials":1875,"activeCount":52},[],{"trials":1877,"activeCount":52},[],{"intervention":1879,"totalTrials":8,"cells":1880},"Canagliflozin",{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1893,"PHASE3":1895,"PHASE4":1897,"NA":1899},{"trials":1882,"activeCount":52},[],{"trials":1884,"activeCount":52},[1885],{"nctId":1886,"briefTitle":1887,"status":64,"phases":1888,"primaryCompletion":418,"completion":418,"start":1889,"enrollment":844,"conditions":1890,"interventions":1891},"NCT01877889","A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers",[42],"2013-07",[14],[1879,1892],"Dapagliflozin",{"trials":1894,"activeCount":52},[],{"trials":1896,"activeCount":52},[],{"trials":1898,"activeCount":52},[],{"trials":1900,"activeCount":52},[],{"intervention":1892,"totalTrials":8,"cells":1902},{"EARLY_PHASE1":1903,"PHASE1":1905,"PHASE2":1911,"PHASE3":1913,"PHASE4":1915,"NA":1917},{"trials":1904,"activeCount":52},[],{"trials":1906,"activeCount":52},[1907],{"nctId":1886,"briefTitle":1887,"status":64,"phases":1908,"primaryCompletion":418,"completion":418,"start":1889,"enrollment":844,"conditions":1909,"interventions":1910},[42],[14],[1879,1892],{"trials":1912,"activeCount":52},[],{"trials":1914,"activeCount":52},[],{"trials":1916,"activeCount":52},[],{"trials":1918,"activeCount":52},[],{"intervention":1920,"totalTrials":8,"cells":1921},"JNJ-61393215",{"EARLY_PHASE1":1922,"PHASE1":1924,"PHASE2":1934,"PHASE3":1936,"PHASE4":1938,"NA":1940},{"trials":1923,"activeCount":52},[],{"trials":1925,"activeCount":52},[1926],{"nctId":1927,"briefTitle":1928,"status":64,"phases":1929,"primaryCompletion":1930,"completion":1930,"start":1931,"enrollment":384,"conditions":1932,"interventions":1933},"NCT02812251","Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy Participants",[42],"2016-11-17","2016-07-07",[14],[1920],{"trials":1935,"activeCount":52},[],{"trials":1937,"activeCount":52},[],{"trials":1939,"activeCount":52},[],{"trials":1941,"activeCount":52},[],{"intervention":1943,"totalTrials":8,"cells":1944},"JNJ 54175446",{"EARLY_PHASE1":1945,"PHASE1":1947,"PHASE2":1956,"PHASE3":1958,"PHASE4":1960,"NA":1962},{"trials":1946,"activeCount":52},[],{"trials":1948,"activeCount":52},[1949],{"nctId":1950,"briefTitle":1951,"status":64,"phases":1952,"primaryCompletion":1496,"completion":1496,"start":1953,"enrollment":1787,"conditions":1954,"interventions":1955},"NCT02475148","A Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Participants",[42],"2015-06",[14],[1943],{"trials":1957,"activeCount":52},[],{"trials":1959,"activeCount":52},[],{"trials":1961,"activeCount":52},[],{"trials":1963,"activeCount":52},[],{"intervention":1712,"totalTrials":8,"cells":1965},{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1967,"activeCount":52},[],{"trials":1969,"activeCount":52},[1970],{"nctId":1703,"briefTitle":1704,"status":64,"phases":1971,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":1708,"conditions":1972,"interventions":1973},[42],[1710],[1688,1712],{"trials":1975,"activeCount":52},[],{"trials":1977,"activeCount":52},[],{"trials":1979,"activeCount":52},[],{"trials":1981,"activeCount":52},[],{"intervention":1983,"totalTrials":8,"cells":1984},"JNJ-55308942 High Dose",{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":2001,"PHASE3":2003,"PHASE4":2005,"NA":2007},{"trials":1986,"activeCount":52},[],{"trials":1988,"activeCount":52},[1989],{"nctId":1990,"briefTitle":1991,"status":64,"phases":1992,"primaryCompletion":1993,"completion":1993,"start":1994,"enrollment":1995,"conditions":1996,"interventions":1997},"NCT03547024","A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel\u002FEthinyl Estradiol",[42],"2018-08-30","2018-06-08",14,[14],[1983,1998,1999,2000],"JNJ-55308942 Low Dose","Levonorgestrel\u002FEthinyl Estradiol Fixed Dose combination","Drug Cocktail:Midazolam",{"trials":2002,"activeCount":52},[],{"trials":2004,"activeCount":52},[],{"trials":2006,"activeCount":52},[],{"trials":2008,"activeCount":52},[],{"intervention":1998,"totalTrials":8,"cells":2010},{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2019,"PHASE3":2021,"PHASE4":2023,"NA":2025},{"trials":2012,"activeCount":52},[],{"trials":2014,"activeCount":52},[2015],{"nctId":1990,"briefTitle":1991,"status":64,"phases":2016,"primaryCompletion":1993,"completion":1993,"start":1994,"enrollment":1995,"conditions":2017,"interventions":2018},[42],[14],[1983,1998,1999,2000],{"trials":2020,"activeCount":52},[],{"trials":2022,"activeCount":52},[],{"trials":2024,"activeCount":52},[],{"trials":2026,"activeCount":52},[],{"intervention":1999,"totalTrials":8,"cells":2028},{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2037,"PHASE3":2039,"PHASE4":2041,"NA":2043},{"trials":2030,"activeCount":52},[],{"trials":2032,"activeCount":52},[2033],{"nctId":1990,"briefTitle":1991,"status":64,"phases":2034,"primaryCompletion":1993,"completion":1993,"start":1994,"enrollment":1995,"conditions":2035,"interventions":2036},[42],[14],[1983,1998,1999,2000],{"trials":2038,"activeCount":52},[],{"trials":2040,"activeCount":52},[],{"trials":2042,"activeCount":52},[],{"trials":2044,"activeCount":52},[],{"intervention":2000,"totalTrials":8,"cells":2046},{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2055,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2048,"activeCount":52},[],{"trials":2050,"activeCount":52},[2051],{"nctId":1990,"briefTitle":1991,"status":64,"phases":2052,"primaryCompletion":1993,"completion":1993,"start":1994,"enrollment":1995,"conditions":2053,"interventions":2054},[42],[14],[1983,1998,1999,2000],{"trials":2056,"activeCount":52},[],{"trials":2058,"activeCount":52},[],{"trials":2060,"activeCount":52},[],{"trials":2062,"activeCount":52},[],{"intervention":1721,"totalTrials":8,"cells":2064},{"EARLY_PHASE1":2065,"PHASE1":2067,"PHASE2":2073,"PHASE3":2075,"PHASE4":2077,"NA":2079},{"trials":2066,"activeCount":52},[],{"trials":2068,"activeCount":52},[2069],{"nctId":1714,"briefTitle":1715,"status":64,"phases":2070,"primaryCompletion":1717,"completion":1717,"start":1718,"enrollment":9,"conditions":2071,"interventions":2072},[42],[14],[1721,1688],{"trials":2074,"activeCount":52},[],{"trials":2076,"activeCount":52},[],{"trials":2078,"activeCount":52},[],{"trials":2080,"activeCount":52},[],{"intervention":2082,"totalTrials":8,"cells":2083},"Canagliflozin 300 mg",{"EARLY_PHASE1":2084,"PHASE1":2086,"PHASE2":2098,"PHASE3":2100,"PHASE4":2102,"NA":2104},{"trials":2085,"activeCount":52},[],{"trials":2087,"activeCount":52},[2088],{"nctId":2089,"briefTitle":2090,"status":64,"phases":2091,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":995,"conditions":2094,"interventions":2095},"NCT01665638","Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers",[42],"2012-10","2012-09",[14],[2082,2096,2097],"Somatostatin","C-peptide",{"trials":2099,"activeCount":52},[],{"trials":2101,"activeCount":52},[],{"trials":2103,"activeCount":52},[],{"trials":2105,"activeCount":52},[],{"intervention":2096,"totalTrials":8,"cells":2107},{"EARLY_PHASE1":2108,"PHASE1":2110,"PHASE2":2116,"PHASE3":2118,"PHASE4":2120,"NA":2122},{"trials":2109,"activeCount":52},[],{"trials":2111,"activeCount":52},[2112],{"nctId":2089,"briefTitle":2090,"status":64,"phases":2113,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":995,"conditions":2114,"interventions":2115},[42],[14],[2082,2096,2097],{"trials":2117,"activeCount":52},[],{"trials":2119,"activeCount":52},[],{"trials":2121,"activeCount":52},[],{"trials":2123,"activeCount":52},[],{"intervention":2097,"totalTrials":8,"cells":2125},{"EARLY_PHASE1":2126,"PHASE1":2128,"PHASE2":2134,"PHASE3":2136,"PHASE4":2138,"NA":2140},{"trials":2127,"activeCount":52},[],{"trials":2129,"activeCount":52},[2130],{"nctId":2089,"briefTitle":2090,"status":64,"phases":2131,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":995,"conditions":2132,"interventions":2133},[42],[14],[2082,2096,2097],{"trials":2135,"activeCount":52},[],{"trials":2137,"activeCount":52},[],{"trials":2139,"activeCount":52},[],{"trials":2141,"activeCount":52},[],{"intervention":2143,"totalTrials":8,"cells":2144},"CNTO 6785 1 mg\u002Fkg IV",{"EARLY_PHASE1":2145,"PHASE1":2147,"PHASE2":2160,"PHASE3":2162,"PHASE4":2164,"NA":2166},{"trials":2146,"activeCount":52},[],{"trials":2148,"activeCount":52},[2149],{"nctId":2150,"briefTitle":2151,"status":64,"phases":2152,"primaryCompletion":67,"completion":67,"start":2153,"enrollment":2154,"conditions":2155,"interventions":2156},"NCT01288196","A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers",[42],"2011-02",32,[14],[2143,2157,2158,2159],"CNTO 6785 3 mg\u002Fkg IV","CNTO 6785 10 mg\u002Fkg IV","CNTO 6785 SC",{"trials":2161,"activeCount":52},[],{"trials":2163,"activeCount":52},[],{"trials":2165,"activeCount":52},[],{"trials":2167,"activeCount":52},[],{"intervention":2157,"totalTrials":8,"cells":2169},{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2178,"PHASE3":2180,"PHASE4":2182,"NA":2184},{"trials":2171,"activeCount":52},[],{"trials":2173,"activeCount":52},[2174],{"nctId":2150,"briefTitle":2151,"status":64,"phases":2175,"primaryCompletion":67,"completion":67,"start":2153,"enrollment":2154,"conditions":2176,"interventions":2177},[42],[14],[2143,2157,2158,2159],{"trials":2179,"activeCount":52},[],{"trials":2181,"activeCount":52},[],{"trials":2183,"activeCount":52},[],{"trials":2185,"activeCount":52},[],{"intervention":2158,"totalTrials":8,"cells":2187},{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2196,"PHASE3":2198,"PHASE4":2200,"NA":2202},{"trials":2189,"activeCount":52},[],{"trials":2191,"activeCount":52},[2192],{"nctId":2150,"briefTitle":2151,"status":64,"phases":2193,"primaryCompletion":67,"completion":67,"start":2153,"enrollment":2154,"conditions":2194,"interventions":2195},[42],[14],[2143,2157,2158,2159],{"trials":2197,"activeCount":52},[],{"trials":2199,"activeCount":52},[],{"trials":2201,"activeCount":52},[],{"trials":2203,"activeCount":52},[],{"intervention":2159,"totalTrials":8,"cells":2205},{"EARLY_PHASE1":2206,"PHASE1":2208,"PHASE2":2214,"PHASE3":2216,"PHASE4":2218,"NA":2220},{"trials":2207,"activeCount":52},[],{"trials":2209,"activeCount":52},[2210],{"nctId":2150,"briefTitle":2151,"status":64,"phases":2211,"primaryCompletion":67,"completion":67,"start":2153,"enrollment":2154,"conditions":2212,"interventions":2213},[42],[14],[2143,2157,2158,2159],{"trials":2215,"activeCount":52},[],{"trials":2217,"activeCount":52},[],{"trials":2219,"activeCount":52},[],{"trials":2221,"activeCount":52},[],{"intervention":1790,"totalTrials":8,"cells":2223},{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2232,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2225,"activeCount":52},[],{"trials":2227,"activeCount":52},[2228],{"nctId":1783,"briefTitle":1784,"status":64,"phases":2229,"primaryCompletion":1786,"completion":1786,"start":475,"enrollment":1787,"conditions":2230,"interventions":2231},[42],[14],[1766,1790,1791],{"trials":2233,"activeCount":52},[],{"trials":2235,"activeCount":52},[],{"trials":2237,"activeCount":52},[],{"trials":2239,"activeCount":52},[],{"intervention":1791,"totalTrials":8,"cells":2241},{"EARLY_PHASE1":2242,"PHASE1":2244,"PHASE2":2250,"PHASE3":2252,"PHASE4":2254,"NA":2256},{"trials":2243,"activeCount":52},[],{"trials":2245,"activeCount":52},[2246],{"nctId":1783,"briefTitle":1784,"status":64,"phases":2247,"primaryCompletion":1786,"completion":1786,"start":475,"enrollment":1787,"conditions":2248,"interventions":2249},[42],[14],[1766,1790,1791],{"trials":2251,"activeCount":52},[],{"trials":2253,"activeCount":52},[],{"trials":2255,"activeCount":52},[],{"trials":2257,"activeCount":52},[],{"intervention":2259,"totalTrials":8,"cells":2260},"JNJ-42165279 2.5 - 500 mg",{"EARLY_PHASE1":2261,"PHASE1":2263,"PHASE2":2275,"PHASE3":2277,"PHASE4":2279,"NA":2281},{"trials":2262,"activeCount":52},[],{"trials":2264,"activeCount":52},[2265],{"nctId":2266,"briefTitle":2267,"status":64,"phases":2268,"primaryCompletion":2269,"completion":2269,"start":67,"enrollment":1655,"conditions":2270,"interventions":2273},"NCT01650597","A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants",[42],"2012-05",[2271,2272],"Healthy Volunteers","Pharmacokinetics",[2259,2274],"JNJ-42165279 100 mg",{"trials":2276,"activeCount":52},[],{"trials":2278,"activeCount":52},[],{"trials":2280,"activeCount":52},[],{"trials":2282,"activeCount":52},[],{"intervention":2274,"totalTrials":8,"cells":2284},{"EARLY_PHASE1":2285,"PHASE1":2287,"PHASE2":2293,"PHASE3":2295,"PHASE4":2297,"NA":2299},{"trials":2286,"activeCount":52},[],{"trials":2288,"activeCount":52},[2289],{"nctId":2266,"briefTitle":2267,"status":64,"phases":2290,"primaryCompletion":2269,"completion":2269,"start":67,"enrollment":1655,"conditions":2291,"interventions":2292},[42],[2271,2272],[2259,2274],{"trials":2294,"activeCount":52},[],{"trials":2296,"activeCount":52},[],{"trials":2298,"activeCount":52},[],{"trials":2300,"activeCount":52},[],{"intervention":2302,"totalTrials":8,"cells":2303},"JNJ-42847922 5 mg",{"EARLY_PHASE1":2304,"PHASE1":2306,"PHASE2":2320,"PHASE3":2322,"PHASE4":2324,"NA":2326},{"trials":2305,"activeCount":52},[],{"trials":2307,"activeCount":52},[2308],{"nctId":2309,"briefTitle":2310,"status":64,"phases":2311,"primaryCompletion":2312,"completion":2312,"start":2313,"enrollment":2314,"conditions":2315,"interventions":2316},"NCT02230878","A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants",[42],"2014-11","2014-05",40,[14],[2302,2317,2318,2319],"JNJ-42847922 10 mg","JNJ-42847922 20 mg","JNJ-42847922 40 mg",{"trials":2321,"activeCount":52},[],{"trials":2323,"activeCount":52},[],{"trials":2325,"activeCount":52},[],{"trials":2327,"activeCount":52},[],{"intervention":2317,"totalTrials":8,"cells":2329},{"EARLY_PHASE1":2330,"PHASE1":2332,"PHASE2":2338,"PHASE3":2340,"PHASE4":2342,"NA":2344},{"trials":2331,"activeCount":52},[],{"trials":2333,"activeCount":52},[2334],{"nctId":2309,"briefTitle":2310,"status":64,"phases":2335,"primaryCompletion":2312,"completion":2312,"start":2313,"enrollment":2314,"conditions":2336,"interventions":2337},[42],[14],[2302,2317,2318,2319],{"trials":2339,"activeCount":52},[],{"trials":2341,"activeCount":52},[],{"trials":2343,"activeCount":52},[],{"trials":2345,"activeCount":52},[],{"intervention":2318,"totalTrials":8,"cells":2347},{"EARLY_PHASE1":2348,"PHASE1":2350,"PHASE2":2356,"PHASE3":2358,"PHASE4":2360,"NA":2362},{"trials":2349,"activeCount":52},[],{"trials":2351,"activeCount":52},[2352],{"nctId":2309,"briefTitle":2310,"status":64,"phases":2353,"primaryCompletion":2312,"completion":2312,"start":2313,"enrollment":2314,"conditions":2354,"interventions":2355},[42],[14],[2302,2317,2318,2319],{"trials":2357,"activeCount":52},[],{"trials":2359,"activeCount":52},[],{"trials":2361,"activeCount":52},[],{"trials":2363,"activeCount":52},[],{"intervention":2319,"totalTrials":8,"cells":2365},{"EARLY_PHASE1":2366,"PHASE1":2368,"PHASE2":2374,"PHASE3":2376,"PHASE4":2378,"NA":2380},{"trials":2367,"activeCount":52},[],{"trials":2369,"activeCount":52},[2370],{"nctId":2309,"briefTitle":2310,"status":64,"phases":2371,"primaryCompletion":2312,"completion":2312,"start":2313,"enrollment":2314,"conditions":2372,"interventions":2373},[42],[14],[2302,2317,2318,2319],{"trials":2375,"activeCount":52},[],{"trials":2377,"activeCount":52},[],{"trials":2379,"activeCount":52},[],{"trials":2381,"activeCount":52},[],{"intervention":1668,"totalTrials":8,"cells":2383},{"EARLY_PHASE1":2384,"PHASE1":2386,"PHASE2":2392,"PHASE3":2394,"PHASE4":2396,"NA":2398},{"trials":2385,"activeCount":52},[],{"trials":2387,"activeCount":52},[2388],{"nctId":1659,"briefTitle":1660,"status":64,"phases":2389,"primaryCompletion":1662,"completion":1663,"start":1664,"enrollment":1665,"conditions":2390,"interventions":2391},[42],[14],[1643,1668],{"trials":2393,"activeCount":52},[],{"trials":2395,"activeCount":52},[],{"trials":2397,"activeCount":52},[],{"trials":2399,"activeCount":52},[],{"intervention":2401,"totalTrials":8,"cells":2402},"JNJ-48816274",{"EARLY_PHASE1":2403,"PHASE1":2405,"PHASE2":2416,"PHASE3":2418,"PHASE4":2420,"NA":2422},{"trials":2404,"activeCount":52},[],{"trials":2406,"activeCount":52},[2407],{"nctId":2408,"briefTitle":2409,"status":64,"phases":2410,"primaryCompletion":2411,"completion":2411,"start":2412,"enrollment":2413,"conditions":2414,"interventions":2415},"NCT02852395","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274",[42],"2018-05-02","2016-08-13",90,[14],[2401],{"trials":2417,"activeCount":52},[],{"trials":2419,"activeCount":52},[],{"trials":2421,"activeCount":52},[],{"trials":2423,"activeCount":52},[],{"intervention":2425,"totalTrials":8,"cells":2426},"JNJ-55308942",{"EARLY_PHASE1":2427,"PHASE1":2429,"PHASE2":2441,"PHASE3":2443,"PHASE4":2445,"NA":2447},{"trials":2428,"activeCount":52},[],{"trials":2430,"activeCount":52},[2431],{"nctId":2432,"briefTitle":2433,"status":64,"phases":2434,"primaryCompletion":2435,"completion":2435,"start":2436,"enrollment":2437,"conditions":2438,"interventions":2439},"NCT03437590","A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739",[42],"2018-10-19","2018-03-15",13,[14],[2425,2440],"[18F]-JNJ-64413739",{"trials":2442,"activeCount":52},[],{"trials":2444,"activeCount":52},[],{"trials":2446,"activeCount":52},[],{"trials":2448,"activeCount":52},[],{"intervention":2440,"totalTrials":8,"cells":2450},{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2459,"PHASE3":2461,"PHASE4":2463,"NA":2465},{"trials":2452,"activeCount":52},[],{"trials":2454,"activeCount":52},[2455],{"nctId":2432,"briefTitle":2433,"status":64,"phases":2456,"primaryCompletion":2435,"completion":2435,"start":2436,"enrollment":2437,"conditions":2457,"interventions":2458},[42],[14],[2425,2440],{"trials":2460,"activeCount":52},[],{"trials":2462,"activeCount":52},[],{"trials":2464,"activeCount":52},[],{"trials":2466,"activeCount":52},[],{"intervention":2468,"totalTrials":8,"cells":2469},"JNJ-55308942 0.5 mg",{"EARLY_PHASE1":2470,"PHASE1":2472,"PHASE2":2490,"PHASE3":2492,"PHASE4":2494,"NA":2496},{"trials":2471,"activeCount":52},[],{"trials":2473,"activeCount":52},[2474],{"nctId":2475,"briefTitle":2476,"status":64,"phases":2477,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":2480,"conditions":2481,"interventions":2482},"NCT03151486","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Participants",[42],"2018-03-08","2017-05-03",98,[14],[2468,2483,2484,2485,2486,2487,2488,2489],"JNJ-55308942 1.5 mg","JNJ-55308942 4 mg","JNJ-55308942 12 mg","JNJ-55308942 36 mg","JNJ-55308942 100 mg","JNJ-55308942: Fed State","JNJ-55308942: MAD Part",{"trials":2491,"activeCount":52},[],{"trials":2493,"activeCount":52},[],{"trials":2495,"activeCount":52},[],{"trials":2497,"activeCount":52},[],{"intervention":2483,"totalTrials":8,"cells":2499},{"EARLY_PHASE1":2500,"PHASE1":2502,"PHASE2":2508,"PHASE3":2510,"PHASE4":2512,"NA":2514},{"trials":2501,"activeCount":52},[],{"trials":2503,"activeCount":52},[2504],{"nctId":2475,"briefTitle":2476,"status":64,"phases":2505,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":2480,"conditions":2506,"interventions":2507},[42],[14],[2468,2483,2484,2485,2486,2487,2488,2489],{"trials":2509,"activeCount":52},[],{"trials":2511,"activeCount":52},[],{"trials":2513,"activeCount":52},[],{"trials":2515,"activeCount":52},[],{"intervention":2484,"totalTrials":8,"cells":2517},{"EARLY_PHASE1":2518,"PHASE1":2520,"PHASE2":2526,"PHASE3":2528,"PHASE4":2530,"NA":2532},{"trials":2519,"activeCount":52},[],{"trials":2521,"activeCount":52},[2522],{"nctId":2475,"briefTitle":2476,"status":64,"phases":2523,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":2480,"conditions":2524,"interventions":2525},[42],[14],[2468,2483,2484,2485,2486,2487,2488,2489],{"trials":2527,"activeCount":52},[],{"trials":2529,"activeCount":52},[],{"trials":2531,"activeCount":52},[],{"trials":2533,"activeCount":52},[],{"intervention":2485,"totalTrials":8,"cells":2535},{"EARLY_PHASE1":2536,"PHASE1":2538,"PHASE2":2544,"PHASE3":2546,"PHASE4":2548,"NA":2550},{"trials":2537,"activeCount":52},[],{"trials":2539,"activeCount":52},[2540],{"nctId":2475,"briefTitle":2476,"status":64,"phases":2541,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":2480,"conditions":2542,"interventions":2543},[42],[14],[2468,2483,2484,2485,2486,2487,2488,2489],{"trials":2545,"activeCount":52},[],{"trials":2547,"activeCount":52},[],{"trials":2549,"activeCount":52},[],{"trials":2551,"activeCount":52},[],{"intervention":2486,"totalTrials":8,"cells":2553},{"EARLY_PHASE1":2554,"PHASE1":2556,"PHASE2":2562,"PHASE3":2564,"PHASE4":2566,"NA":2568},{"trials":2555,"activeCount":52},[],{"trials":2557,"activeCount":52},[2558],{"nctId":2475,"briefTitle":2476,"status":64,"phases":2559,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":2480,"conditions":2560,"interventions":2561},[42],[14],[2468,2483,2484,2485,2486,2487,2488,2489],{"trials":2563,"activeCount":52},[],{"trials":2565,"activeCount":52},[],{"trials":2567,"activeCount":52},[],{"trials":2569,"activeCount":52},[],{"intervention":2487,"totalTrials":8,"cells":2571},{"EARLY_PHASE1":2572,"PHASE1":2574,"PHASE2":2580,"PHASE3":2582,"PHASE4":2584,"NA":2586},{"trials":2573,"activeCount":52},[],{"trials":2575,"activeCount":52},[2576],{"nctId":2475,"briefTitle":2476,"status":64,"phases":2577,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":2480,"conditions":2578,"interventions":2579},[42],[14],[2468,2483,2484,2485,2486,2487,2488,2489],{"trials":2581,"activeCount":52},[],{"trials":2583,"activeCount":52},[],{"trials":2585,"activeCount":52},[],{"trials":2587,"activeCount":52},[],{"intervention":2488,"totalTrials":8,"cells":2589},{"EARLY_PHASE1":2590,"PHASE1":2592,"PHASE2":2598,"PHASE3":2600,"PHASE4":2602,"NA":2604},{"trials":2591,"activeCount":52},[],{"trials":2593,"activeCount":52},[2594],{"nctId":2475,"briefTitle":2476,"status":64,"phases":2595,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":2480,"conditions":2596,"interventions":2597},[42],[14],[2468,2483,2484,2485,2486,2487,2488,2489],{"trials":2599,"activeCount":52},[],{"trials":2601,"activeCount":52},[],{"trials":2603,"activeCount":52},[],{"trials":2605,"activeCount":52},[],{"intervention":2489,"totalTrials":8,"cells":2607},{"EARLY_PHASE1":2608,"PHASE1":2610,"PHASE2":2616,"PHASE3":2618,"PHASE4":2620,"NA":2622},{"trials":2609,"activeCount":52},[],{"trials":2611,"activeCount":52},[2612],{"nctId":2475,"briefTitle":2476,"status":64,"phases":2613,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":2480,"conditions":2614,"interventions":2615},[42],[14],[2468,2483,2484,2485,2486,2487,2488,2489],{"trials":2617,"activeCount":52},[],{"trials":2619,"activeCount":52},[],{"trials":2621,"activeCount":52},[],{"trials":2623,"activeCount":52},[],{"intervention":1756,"totalTrials":8,"cells":2625},{"EARLY_PHASE1":2626,"PHASE1":2628,"PHASE2":2634,"PHASE3":2636,"PHASE4":2638,"NA":2640},{"trials":2627,"activeCount":52},[],{"trials":2629,"activeCount":52},[2630],{"nctId":1748,"briefTitle":1749,"status":64,"phases":2631,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":1753,"conditions":2632,"interventions":2633},[42],[14],[1731,1756],{"trials":2635,"activeCount":52},[],{"trials":2637,"activeCount":52},[],{"trials":2639,"activeCount":52},[],{"trials":2641,"activeCount":52},[],{"intervention":2643,"totalTrials":8,"cells":2644},"JNJ-42396302",{"EARLY_PHASE1":2645,"PHASE1":2647,"PHASE2":2658,"PHASE3":2660,"PHASE4":2662,"NA":2664},{"trials":2646,"activeCount":52},[],{"trials":2648,"activeCount":52},[2649],{"nctId":2650,"briefTitle":2651,"status":64,"phases":2652,"primaryCompletion":2092,"completion":2092,"start":2653,"enrollment":1665,"conditions":2654,"interventions":2655},"NCT01732237","A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants",[42],"2012-08",[14],[2643,2656,2657],"JNJ-42692507","JNJ-53773187",{"trials":2659,"activeCount":52},[],{"trials":2661,"activeCount":52},[],{"trials":2663,"activeCount":52},[],{"trials":2665,"activeCount":52},[],{"intervention":2656,"totalTrials":8,"cells":2667},{"EARLY_PHASE1":2668,"PHASE1":2670,"PHASE2":2676,"PHASE3":2678,"PHASE4":2680,"NA":2682},{"trials":2669,"activeCount":52},[],{"trials":2671,"activeCount":52},[2672],{"nctId":2650,"briefTitle":2651,"status":64,"phases":2673,"primaryCompletion":2092,"completion":2092,"start":2653,"enrollment":1665,"conditions":2674,"interventions":2675},[42],[14],[2643,2656,2657],{"trials":2677,"activeCount":52},[],{"trials":2679,"activeCount":52},[],{"trials":2681,"activeCount":52},[],{"trials":2683,"activeCount":52},[],{"intervention":2657,"totalTrials":8,"cells":2685},{"EARLY_PHASE1":2686,"PHASE1":2688,"PHASE2":2694,"PHASE3":2696,"PHASE4":2698,"NA":2700},{"trials":2687,"activeCount":52},[],{"trials":2689,"activeCount":52},[2690],{"nctId":2650,"briefTitle":2651,"status":64,"phases":2691,"primaryCompletion":2092,"completion":2092,"start":2653,"enrollment":1665,"conditions":2692,"interventions":2693},[42],[14],[2643,2656,2657],{"trials":2695,"activeCount":52},[],{"trials":2697,"activeCount":52},[],{"trials":2699,"activeCount":52},[],{"trials":2701,"activeCount":52},[],{"intervention":2703,"totalTrials":8,"cells":2704},"Telaprevir + peginterferon alfa + ribavirin",{"EARLY_PHASE1":2705,"PHASE1":2707,"PHASE2":2709,"PHASE3":2711,"PHASE4":2713,"NA":2715},{"trials":2706,"activeCount":52},[],{"trials":2708,"activeCount":52},[],{"trials":2710,"activeCount":52},[],{"trials":2712,"activeCount":52},[],{"trials":2714,"activeCount":52},[],{"trials":2716,"activeCount":52},[2717],{"nctId":2718,"briefTitle":2719,"status":2720,"phases":2721,"conditions":2722,"interventions":2723},"NCT01508286","Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects","NO_LONGER_AVAILABLE",[],[28],[2703,2724,2724],"peginterferon alfa + ribavirin",{"intervention":2724,"totalTrials":8,"cells":2726},{"EARLY_PHASE1":2727,"PHASE1":2729,"PHASE2":2731,"PHASE3":2733,"PHASE4":2735,"NA":2737},{"trials":2728,"activeCount":52},[],{"trials":2730,"activeCount":52},[],{"trials":2732,"activeCount":52},[],{"trials":2734,"activeCount":52},[],{"trials":2736,"activeCount":52},[],{"trials":2738,"activeCount":52},[2739],{"nctId":2718,"briefTitle":2719,"status":2720,"phases":2740,"conditions":2741,"interventions":2742},[],[28],[2703,2724,2724],{"intervention":2744,"totalTrials":8,"cells":2745},"Risperidone Long-Acting injectable or oral antipsychotics",{"EARLY_PHASE1":2746,"PHASE1":2748,"PHASE2":2750,"PHASE3":2752,"PHASE4":2754,"NA":2756},{"trials":2747,"activeCount":52},[],{"trials":2749,"activeCount":52},[],{"trials":2751,"activeCount":52},[],{"trials":2753,"activeCount":52},[],{"trials":2755,"activeCount":52},[],{"trials":2757,"activeCount":52},[2758],{"nctId":2759,"briefTitle":2760,"status":64,"phases":2761,"primaryCompletion":2762,"completion":2762,"start":705,"enrollment":2763,"conditions":2764,"interventions":2765},"NCT01026285","InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics",[],"2012-03",1085,[17],[2744],{"intervention":2767,"totalTrials":8,"cells":2768},"Bortezomib, tradename Velcade",{"EARLY_PHASE1":2769,"PHASE1":2771,"PHASE2":2773,"PHASE3":2775,"PHASE4":2777,"NA":2779},{"trials":2770,"activeCount":52},[],{"trials":2772,"activeCount":52},[],{"trials":2774,"activeCount":52},[],{"trials":2776,"activeCount":52},[],{"trials":2778,"activeCount":52},[],{"trials":2780,"activeCount":52},[2781],{"nctId":2782,"briefTitle":2783,"status":64,"phases":2784,"completion":2785,"start":2786,"enrollment":2787,"conditions":2788,"interventions":2789},"NCT00440635","Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma",[],"2006-10","2004-01",641,[20],[2767],{"intervention":2791,"totalTrials":8,"cells":2792},"Paliperidone Palmitate 3-Month Formulation",{"EARLY_PHASE1":2793,"PHASE1":2795,"PHASE2":2797,"PHASE3":2799,"PHASE4":2801,"NA":2803},{"trials":2794,"activeCount":52},[],{"trials":2796,"activeCount":52},[],{"trials":2798,"activeCount":52},[],{"trials":2800,"activeCount":52},[],{"trials":2802,"activeCount":52},[],{"trials":2804,"activeCount":52},[2805],{"nctId":2806,"briefTitle":2807,"status":64,"phases":2808,"primaryCompletion":2809,"completion":2809,"start":2810,"enrollment":2811,"conditions":2812,"interventions":2813},"NCT03809325","A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly",[],"2019-07-12","2018-11-21",225,[17],[2791],{"intervention":2815,"totalTrials":8,"cells":2816},"No intervention",{"EARLY_PHASE1":2817,"PHASE1":2819,"PHASE2":2821,"PHASE3":2823,"PHASE4":2825,"NA":2827},{"trials":2818,"activeCount":52},[],{"trials":2820,"activeCount":52},[],{"trials":2822,"activeCount":52},[],{"trials":2824,"activeCount":52},[],{"trials":2826,"activeCount":52},[],{"trials":2828,"activeCount":52},[2829],{"nctId":2830,"briefTitle":2831,"status":64,"phases":2832,"primaryCompletion":429,"completion":429,"start":2833,"enrollment":2834,"conditions":2835,"interventions":2836},"NCT01926912","A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting",[],"2013-05",371,[17],[2815]]